{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "7582300", "DateCompleted": {"Year": "1995", "Month": "12", "Day": "06"}, "DateRevised": {"Year": "2013", "Month": "11", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "1073-449X", "JournalIssue": {"Volume": "152", "Issue": "5 Pt 1", "PubDate": {"Year": "1995", "Month": "Nov"}}, "Title": "American journal of respiratory and critical care medicine", "ISOAbbreviation": "Am J Respir Crit Care Med"}, "ArticleTitle": "Contribution of secretory leukocyte proteinase inhibitor to the antiprotease defense system of the peripheral lung: effect of ozone-induced acute inflammation.", "Pagination": {"StartPage": "1592", "EndPage": "1598", "MedlinePgn": "1592-8"}, "Abstract": {"AbstractText": ["Secretory leukocyte protease inhibitor (SLPI) and elafin are structurally similar, low-molecular-weight antiproteases produced in the lung. We have developed a simple method for distinguishing the antiprotease activities of SLPI and elafin in lung lavage fluid from those of alpha 1-antitrypsin (alpha 1-AT) that is based on the resistance of the low-molecular-weight antiproteases to inactivation by cetyltrimethylammonium bromide. In a study of 23 healthy, nonsmoking volunteers, we found that the low-molecular-weight antiproteases accounted for 22 +/- 2% (mean +/- SEM, n = 23) of the total neutrophil elastase-inhibitory capacity of human bronchoalveolar lavage fluid (BALF). Elafin activity was below the limit of detection. SLPI activity (as measured by inhibition of alpha-chymotrypsin) accounted for 72 +/- 4% (mean +/- SEM, n = 23) of the low-molecular-weight antiprotease activity in BALF. Measurements of SLPI in the lavage fluid samples by enzyme-linked immunosorbent assay (ELISA) agreed closely with values obtained by measuring the activity of this inhibitor. The activity of the low-molecular-weight antiproteases decreased significantly (p < 0.05), from 9.0 +/- 0.8 to 7.0 +/- 0.6 pmol of neutrophil elastase inhibited per mL (mean +/- SEM, n = 23), following acute ozone exposure."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Environmental Medicine, New York University Medical Center, Tuxedo 10987, USA."}], "Identifier": [], "LastName": "Nadziejko", "ForeName": "C", "Initials": "C"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Finkelstein", "ForeName": "I", "Initials": "I"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Balmes", "ForeName": "J R", "Initials": "JR"}], "GrantList": [{"GrantID": "ES00260", "Acronym": "ES", "Agency": "NIEHS NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Clinical Trial", "Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't", "Research Support, U.S. Gov't, P.H.S."]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Am J Respir Crit Care Med", "NlmUniqueID": "9421642", "ISSNLinking": "1073-449X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Proteinase Inhibitory Proteins, Secretory"}, {"RegistryNumber": "0", "NameOfSubstance": "Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "SLPI protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Secretory Leukocyte Peptidase Inhibitor"}, {"RegistryNumber": "0", "NameOfSubstance": "Serine Proteinase Inhibitors"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Acute Disease"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["chemistry"], "DescriptorName": "Bronchoalveolar Lavage Fluid"}, {"QualifierName": [], "DescriptorName": "Bronchoscopy"}, {"QualifierName": [], "DescriptorName": "Cross-Over Studies"}, {"QualifierName": [], "DescriptorName": "Enzyme-Linked Immunosorbent Assay"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects", "enzymology"], "DescriptorName": "Lung"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Molecular Weight"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Ozone"}, {"QualifierName": ["chemically induced", "enzymology"], "DescriptorName": "Pneumonia"}, {"QualifierName": [], "DescriptorName": "Proteinase Inhibitory Proteins, Secretory"}, {"QualifierName": ["analysis", "physiology"], "DescriptorName": "Proteins"}, {"QualifierName": [], "DescriptorName": "Secretory Leukocyte Peptidase Inhibitor"}, {"QualifierName": ["analysis", "physiology"], "DescriptorName": "Serine Proteinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Single-Blind Method"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "1995", "Month": "11", "Day": "1"}, {"Year": "1995", "Month": "11", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "1995", "Month": "11", "Day": "1", "Hour": "0", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["7582300", "10.1164/ajrccm.152.5.7582300"]}}], "PubmedBookArticle": []}